NCT01176071

Brief Summary

The investigators hypothesize that early galactomannan and beta-D-glucan features, namely the height of the initial value at the time of diagnosis and the subsequent rate of marker decay within the first week(s) following therapy (day 7, day 14) are important factors in predicting clinical outcome.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2010

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 4, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 5, 2010

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
Last Updated

August 5, 2010

Status Verified

July 1, 2010

Enrollment Period

5 months

First QC Date

August 4, 2010

Last Update Submit

August 4, 2010

Conditions

Invasive Aspergillosis

Keywords

galactomannanbeta-D-glucanaspergillosisoutcome

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

hematology patients with proven or probable invasive aspergillosis

You may qualify if:

  • proven or probable invasive aspergillosis with positive GM antigen test

You may not qualify if:

  • Seronegative aspergillosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Aspergillosis

Condition Hierarchy (Ancestors)

MycosesBacterial Infections and MycosesInfections

Study Officials

  • Johan A Maertens, MD, PhD

    UZ Gasthuisberg Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 4, 2010

First Posted

August 5, 2010

Study Start

July 1, 2010

Primary Completion

December 1, 2010

Study Completion

January 1, 2011

Last Updated

August 5, 2010

Record last verified: 2010-07